Tai Eric W, Ward Kevin C, Bonaventure Audrey, Siegel David A, Coleman Michel P
Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
Georgia Center for Cancer Statistics, Emory University, Atlanta, Georgia.
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):5178-5189. doi: 10.1002/cncr.30899.
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. This report describes the survival of children with ALL in the United States using the most comprehensive and up-to-date cancer registry data.
Data from 37 state cancer registries that cover approximately 80% of the US population were used. Age-standardized survival up to 5 years was estimated for children aged 0-14 years who were diagnosed with ALL during 2 periods (2001-2003 and 2004-2009).
In total, 17,500 children with ALL were included. The pooled age-standardized net survival estimates for all US registries combined were 95% at 1 year, 90% at 3 years, and 86% at 5 years for children diagnosed during 2001-2003, and 96%, 91%, and 88%, respectively, for those diagnosed during 2004-2009. Black children who were diagnosed during 2001-2003 had lower 5-year survival (84%) than white children (87%) and had less improvement in survival by 2004-2009. For those diagnosed during 2004-2009, the 1-year and 5-year survival estimates were 96% and 89%, respectively, for white children and 96% and 84%, respectively, for black children. During 2004-2009, survival was highest among children aged 1 to 4 years (95%) and lowest among children aged <1 year (60%).
The current results indicate that overall net survival from childhood ALL in the United States is high, but disparities by race still exist, especially beyond the first year after diagnosis. Clinical and public health strategies are needed to improve health care access, clinical trial enrollment, treatment, and survivorship care for children with ALL. Cancer 2017;123:5178-89. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
急性淋巴细胞白血病(ALL)是儿童期最常见的恶性肿瘤。本报告利用最全面和最新的癌症登记数据描述了美国ALL患儿的生存情况。
使用来自37个州癌症登记处的数据,这些登记处覆盖了约80%的美国人口。对在两个时间段(2001 - 2003年和2004 - 2009年)被诊断为ALL的0至14岁儿童估计了5年的年龄标准化生存率。
总共纳入了17500例ALL患儿。美国所有登记处合并后的年龄标准化净生存估计值显示,2001 - 2003年诊断的患儿1年时为95%,3年时为90%,5年时为86%;2004 - 2009年诊断的患儿相应比例分别为96%、91%和88%。2001 - 2003年诊断的黑人患儿5年生存率(84%)低于白人患儿(87%),到2004 - 2009年生存率改善幅度也较小。对于2004 - 2009年诊断的患儿,白人患儿1年和5年生存估计值分别为96%和89%,黑人患儿分别为96%和84%。在2004 - 2009年期间,1至4岁儿童的生存率最高(95%),<1岁儿童的生存率最低(60%)。
目前的结果表明,美国儿童ALL的总体净生存率较高,但种族差异仍然存在,尤其是在诊断后的第一年之后。需要临床和公共卫生策略来改善ALL患儿的医疗保健可及性、临床试验入组、治疗及生存护理。《癌症》2017年;123:5178 - 89。2017年发表。本文是美国政府作品,在美国属于公共领域。